Return to News

Study on Psilocybin Therapy Eligibility Receives Unprecedented Global Media Coverage

In a landmark paper published in Psychedelics (Genomic Press), researchers have provided the first comprehensive analysis revealing that over 5 million Americans with depression could benefit from psilocybin-assisted therapy if FDA-approved. This groundbreaking study, which exemplifies the innovative research featured in this new peer-reviewed journal, has garnered unprecedented global attention, with coverage in 88 media outlets across 10 languages. The paper's rigorous analysis provides the first data-driven estimates of eligible patients based on real-world clinical criteria, demonstrating Psychedelics’ commitment to publishing research that bridges scientific innovation with practical clinical applications.

Global Impact of Psychedelics

This paper exemplifies Psychedelics’ growing influence as a leading international forum for psychedelic medicine research. Within just days of publication, the study's findings were rapidly disseminated across:

  • North America: Major coverage in English and Spanish media
  • Europe: Translations and coverage in French, Italian, Portuguese, and Spanish outlets
  • Middle East: Featured in Arabic (Egypt) and Hebrew language press
  • Asia: Reaching audiences through Chinese, Indonesian, Vietnamese, and Malay translations
  • Latin America: Extensive coverage in Spanish-language medical and general news media

This swift, worldwide uptake of research published in Psychedelics demonstrates the journal's unique position in facilitating global scientific dialogue about psychedelic medicine.

Study Summary

Researchers examined how many patients currently receiving depression treatment would qualify for psilocybin-assisted therapy based on clinical trial criteria and real-world medical considerations. The study established three key estimates:

  • Lower-bound: 24% of patients (2.2 million) would meet strict clinical trial criteria
  • Mid-range: 56% of patients (5.1 million) would qualify under likely real-world scenarios
  • Upper-bound: 62% of patients (5.6 million) would be eligible when accounting for overlapping medical conditions

Major Media Coverage

The research has been featured in leading news outlets, including:

Newsweek: “Depression: Five Million Americans May Benefit From Psychedelic Therapy”
Key quote: “The findings suggest a significant shift in potential depression treatment options, with millions of Americans potentially qualifying for this novel therapy.”

US News & World Report: “Over 5 Million Americans Could Benefit if Psilocybin Approved for Depression: Study”

Notable coverage highlighting the study's implications for US healthcare policy and treatment accessibility.

Global Media Impact

The research has achieved remarkable international reach, with coverage in:

  • English: Major outlets including Newsweek, US News & World Report, and dozens of regional publications
  • Spanish: Coverage across multiple countries including Newsweek Español and Infobae
  • French: Featured in clinical and news publications
  • Italian: Coverage in AGI and 30Science
  • Portuguese: Medical and health publications
  • Chinese: Healthcare and medical news outlets
  • Arabic: Featured in Egyptian media
  • Hebrew: Medical news coverage
  • Indonesian: Multiple health news outlets
  • Vietnamese: Health and medical publications

Research Details

📝 Article published in Psychedelics (@GenomicPress):
📄🔓 Open Access: https://url.genomicpress.com/yc6v2vcj
🇺🇸 EurekAlert! (EN): https://url.genomicpress.com/y9xe8n9d

The study was conducted by Syed F. Rab from Emory University School of Medicine, in collaboration with Charles L. Raison from the University of Wisconsin-Madison and Elliot Marseille from UC Berkeley's Collaborative for the Economics of Psychedelics.

The extraordinary global media response to this publication in Psychedelics (Genomic Press) - with coverage spanning 88 media outlets across 10 languages - demonstrates not only the growing worldwide interest in psychedelic medicine but also establishes Psychedelics as a leading voice in this rapidly evolving field. This reach across major international media outlets, from Newsweek to China's healthcare press, reflects both the quality of research being published in Psychedelics and the journal's role as a key platform for communicating critical developments in mental health treatment innovation to a global scientific and medical audience.